|
KRR1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62481139653892E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.54538662053983E-13 |
| Normal-vs-Stage2 |
1.59949999911646E-08 |
| Normal-vs-Stage3 |
1.99840144432528E-15 |
| Normal-vs-Stage4 |
1.84596782304425E-12 |
| Stage1-vs-Stage2 |
8.460200E-01 |
| Stage1-vs-Stage3 |
5.099800E-02 |
| Stage1-vs-Stage4 |
2.400300E-02 |
| Stage2-vs-Stage3 |
2.242600E-01 |
| Stage2-vs-Stage4 |
1.621980E-01 |
| Stage3-vs-Stage4 |
7.508800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.66373598126302E-15 |
| Normal-vs-AfricanAmerican |
2.09689999997043E-06 |
| Normal-vs-Asian |
2.73379996418299E-09 |
| Caucasian-vs-AfricanAmerican |
7.566200E-01 |
| Caucasian-vs-Asian |
8.002800E-01 |
| AfricanAmerican-vs-Asian |
9.038600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-16 |
| Normal-vs-Female |
1.64013247427874E-12 |
| Male-vs-Female |
1.214410E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.00206518030654E-12 |
| Normal-vs-Age(41-60Yrs) |
7.70272734484934E-13 |
| Normal-vs-Age(61-80Yrs) |
1.63014046705712E-12 |
| Normal-vs-Age(81-100Yrs) |
3.835200E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.270800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.227360E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.165200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.255600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.444600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.363000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.052200E-02 |
| Classical-VS-Follicular |
5.815600E-01 |
| Classical-VS-Other |
4.367200E-01 |
| Classical-VS-Normal |
1.62636570877339E-12 |
| Tall-VS-Follicular |
2.293200E-01 |
| Tall-VS-Other |
8.824600E-01 |
| Tall-VS-Normal |
2.35199637543815E-11 |
| Follicular-VS-Other |
6.993800E-01 |
| Follicular-VS-Normal |
1.16170000286075E-08 |
| Other-VS-Normal |
8.179100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.88578058618805E-15 |
| Normal-vs-N1 |
2.55430121498534E-11 |
| N0-vs-N1 |
4.734400E-01 |
|
|
